NEW YORK, NY — As October marks Breast Cancer Awareness Month, the familiar landscape of pink ribbons often dominates the public discourse. However, for a significant and often overlooked population, the conversation remains incomplete. While early detection and primary prevention are vital, there exists a critical, life-altering reality that demands equal urgency: Metastatic Breast Cancer (MBC), or Stage 4 breast cancer.
On October 13, National Metastatic Breast Cancer Awareness Day, the nonprofit organization METAvivor Research and Support will spearhead #LightUpMBC, a massive global initiative designed to pull this terminal diagnosis out of the shadows. With more than 325 landmarks spanning 20 countries and 195 cities set to glow in the official awareness colors of teal, green, and pink, the campaign serves as a beacon of solidarity, a call for scientific funding, and a poignant tribute to those whose lives have been irrevocably changed by the disease.
The Reality of Stage 4: What is Metastatic Breast Cancer?
To understand the necessity of the #LightUpMBC movement, one must first confront the medical realities of metastatic breast cancer. MBC occurs when breast cancer cells migrate from the original site in the breast to distant organs, most commonly the bones, liver, lungs, or brain. It is crucial to note that even when the cancer spreads to other organs, it remains classified as breast cancer; it is not, for instance, lung or liver cancer.
For many, MBC is a diagnosis they arrive at after years of remission from early-stage breast cancer. For others, it is the initial diagnosis—Stage 4 from the outset. Regardless of the path, the prognosis remains somber: there is currently no cure.
The treatment trajectory for MBC is fundamentally different from early-stage intervention. It is not about "finishing" treatment; it is about chronic management. Patients exist in a state of perpetual therapy, as cancer cells often develop resistance to treatments, necessitating frequent, often grueling changes in medication. Even when clinical scans show "no evidence of disease," this does not equate to a cure. It simply means the disease is currently being held at bay. The goal of medical intervention in the MBC context is threefold: control the spread, extend the duration of life, and, perhaps most importantly, preserve the quality of that life.
A Chronology of a Movement: From Local Roots to Global Radiance
The #LightUpMBC campaign did not begin in a corporate boardroom, but in the heart of a personal friendship.
2017: The Spark
The movement traces its origins to the Portsmouth Memorial Bridge in New Hampshire. It was here that the campaign began as a singular, local effort to shed light on a condition that was largely ignored by mainstream awareness campaigns.
2017–2025: The Growth Phase
Inspired by the legacy of Jessica Moore, a young woman who lost her battle with MBC at the age of 36, founder Laura Inahara worked to transform her friend’s modest wish—to illuminate one landmark—into a global phenomenon. Over the last decade, the campaign has systematically scaled, moving from a handful of local bridges and municipal buildings to iconic structures including New York City’s One World Trade Center, Chicago’s Willis Tower, and the majestic Niagara Falls.
2026: The Global Pinnacle
This year marks the most ambitious iteration of the campaign to date. With over 325 landmarks participating, the initiative has solidified its position as the premier fundraising engine for the METAvivor research grant program. Having already raised over $2.7 million in previous iterations, the 2026 event seeks to push these figures significantly higher, ensuring that the financial barrier to metastatic research is lowered.
Supporting Data: The Urgent Need for Research
The statistics surrounding MBC are as staggering as they are sobering. According to current projections, approximately 42,670 people in the United States are expected to die from breast cancer in 2026. This translates to a tragic average of 117 deaths every single day.
These numbers represent more than just clinical data points; they represent a systemic failure to provide long-term survival options for those living with Stage 4 disease. Because current awareness initiatives often focus heavily on the "survivor" narrative of early-stage breast cancer, funding for terminal, metastatic research has historically lagged behind.
METAvivor aims to bridge this gap by focusing exclusively on Stage 4 research. The organization employs a rigorous peer-review process, involving both scientific experts and patient advocates, to ensure that every dollar raised is funneled into high-impact, actionable science. The mission is clear: to evolve the medical landscape until MBC is no longer a terminal death sentence, but a manageable, survivable chronic condition.
Official Voices: Perspectives from the Frontline
The #LightUpMBC campaign is anchored by the voices of those who know the disease intimately. Dr. Kelly Shanahan, Board President of METAvivor, has lived with an MBC diagnosis since 2013. Her perspective offers a bridge between the clinical reality and the human experience.
"When I was diagnosed with metastatic breast cancer in 2013, I certainly didn’t think I’d still be here 13 years later," Dr. Shanahan remarked. "My hope and the hope of so many others lies in research, and METAvivor-funded research is increasingly important these days. #LightUpMBC is the biggest contributor to this research, and is also a way to bring us together as a community."
This sentiment of community is echoed by Laura Inahara, who continues to drive the campaign in honor of Jessica Moore. "Jessica hoped to illuminate one local landmark," Inahara reflects. "Today, her legacy helps families around the world shine a light for the people they love, teaches patients with MBC how to advocate for themselves, and has now raised over $2.7 million for critical MBC research."
The Event: #LightUpMBC Live
On the evening of October 13, the movement culminates in #LightUpMBC Live, a digital event designed to humanize the data. The livestream, airing at 8 p.m. ET / 5 p.m. PT, will be hosted by Tami Eagle Bowling—who has lived with MBC for 11 years—and Broadway performer/breast cancer survivor Kara Lindsay.
The program is curated to provide a multifaceted look at the disease:
- Patient Advocacy: Real-time stories from patients standing before illuminated landmarks worldwide.
- Scientific Insight: Expert commentary on the latest breakthroughs and the future of MBC research.
- Cultural Connection: A series of performances by Broadway and music luminaries, including Victoria Clark, Dorian Harewood, Christina Bianco, Cassandra Kubinski, and Tony Daniels.
The event will be available for free on the METAvivor YouTube channel, Facebook Live, and the LiveOne platform, ensuring that the message reaches a global audience without barriers to entry.
Implications: Turning Awareness into Action
The implications of the #LightUpMBC campaign extend far beyond the aesthetic beauty of lit-up monuments. By creating a visual, global spectacle, the campaign forces the public and the medical community to engage with the reality of Stage 4 cancer in a way that static infographics cannot.
The primary objective remains the transformation of the medical paradigm. With 100% of net proceeds from the campaign directed toward research, every dollar is tied to the pursuit of life-extending therapies. For the thousands of families currently navigating the complexities of metastatic treatment, this funding represents the only path toward a different future.
As the landmarks glow in teal, green, and pink this October 13, they serve as more than just symbols of remembrance. They represent a commitment to the living. They are a declaration that patients with Stage 4 cancer are not invisible, that their stories matter, and that with sufficient, targeted research, the horizon for those living with MBC can be expanded.
To join the movement, donate to the cause, or locate a participating landmark, the public is encouraged to visit www.lightupmbc.org. As the sun sets on October 13, the world will see that even in the face of a terminal diagnosis, there is a powerful, persistent light that refuses to go out.
About the Author
